Skip to main content
Genomic Vision logo

Genomic Vision — Investor Relations & Filings

Ticker · GV ISIN · FR0011799907 LEI · 969500UXJNBY1C8Y8471 PA Professional, scientific and technical activities
Open in API
Filings indexed 412 across all filing types
Latest filing 2017-05-23 Regulatory Filings
Country FR France
Listing PA GV

About Genomic Vision

https://www.genomicvision.com/

Genomic Vision is a biotechnology company specializing in the direct visualization and analysis of single DNA molecules through its proprietary Molecular Combing technology. This platform provides highly accurate characterization of large-scale genomic modifications, offering critical insights into genetic integrity and stability. The company's primary focus is on providing quality control (QC) solutions for the bioproduction and cell and gene therapy markets, ensuring the safety and efficacy of advanced therapeutic products. In drug discovery, its Replication Combing Assay (RCA) is used to assess the effects of compounds on DNA replication. Genomic Vision's tools and services support the entire lifecycle of biopharmaceutical development, from research to production.

Recent filings

Filing Released Lang Actions
Communiqués au titre de l'obligation d'information permanente / Autres communiqués
Regulatory Filings Classification · 95% confidence The document is a press release dated May 23, 2017, announcing a technology collaboration between Genomic Vision and AstraZeneca regarding oncology research using Genomic Vision's FiberVision® platform. It details a business development/partnership rather than reporting financial results (ER, IR, 10-K), management changes (MANG), or shareholder votes (DVA). It is a general corporate announcement concerning strategic activity. Since there is no specific category for 'Partnership Announcement' or 'Business Development,' and it is not a formal regulatory filing like a 10-K or a specific report like an AR or SR, the most appropriate general category is 'Regulatory Filings' (RNS) as a catch-all for significant, non-standard corporate news releases, although 'LTR' (Legal Proceedings Report) or 'TAR' (M&A Activity) are clearly incorrect. Given the nature of the announcement (a strategic collaboration), RNS serves as the best fit among the provided options for a general corporate news release.
2017-05-23 French
Communicated under the obligation to provide permanent information / Other communications
Regulatory Filings Classification · 90% confidence The document is a press release dated May 23, 2017, announcing a technological collaboration between Genomic Vision and AstraZeneca regarding the use of the FiberVision® platform in oncology research. It details the nature of the agreement, quotes the CEO, and includes standard boilerplate information (About, Contacts, Forward Looking Statement). This type of announcement, which details a specific business development, partnership, or strategic move, does not fit the definitions for standard financial reports (10-K, IR, ER, AR) or specific corporate actions (DIV, SHA, POS). It is a general business update. Since there is no specific category for 'Partnership Announcement' or 'Business Update', and it is not a transcript (CT), management discussion (MDA), or a proxy/governance document, the most appropriate fallback category is 'Regulatory Filings' (RNS), as it is a formal public announcement intended for the market, often filed with regulators, but doesn't fit the more specific categories.
2017-05-23 English
Communicated under the obligation to provide permanent information / Other communications
Regulatory Filings Classification · 95% confidence The document is titled "GENOMIC VISION: REPORT OF THE IVD R&D DAY OF 10 MAY 2017". It details presentations, discussions, and interim results shared during a specific event (R&D Day) involving the company, partners (Quest Diagnostics, academic teams), and investors/analysts. This content—a summary of presentations given at a specific corporate event—aligns best with the description of materials shared during an Annual General Meeting (AGM-R), although this is an R&D Day, not strictly an AGM. However, among the provided options, 'AGM-R' (AGM Information: Presentations and materials shared during the Annual General Meeting (AGM)) is the closest fit for summarizing a formal presentation event aimed at investors and stakeholders. It is not a full financial report (10-K, IR), an earnings release (ER), or a standard presentation deck (IP), but rather a report *about* the event itself. Given the context of presenting company updates and strategy to stakeholders, AGM-R is the most appropriate classification for this type of event summary.
2017-05-15 English
Communiqués au titre de l'obligation d'information permanente / Autres communiqués
Investor Presentation Classification · 95% confidence The document is titled "GENOMIC VISION : COMPTE-RENDU DU R&D DAY DU 10 MAI 2017 SUR LES PROGRAMMES IVD" (Summary of the R&D Day of May 10, 2017, on IVD Programs). It explicitly states that it is a 'compte-rendu' (summary/report) of an event (R&D Day) where presentations were given by company management, partners (Quest Diagnostics), and academic experts regarding R&D progress, technology potential (molecular combing), and clinical studies (BRCA, SMA, HPV). This content strongly aligns with materials presented during an investor or technical event, which falls under the scope of an Investor Presentation (IP) or potentially a summary of an AGM/Investor Day. Since the focus is heavily on technical R&D updates, partnerships, and future pipeline, 'Investor Presentation' (IP) is the most fitting category, as it summarizes strategic and technical information for investors, even if it's a summary of a dedicated 'R&D Day' event rather than a standard slide deck.
2017-05-15 French
Communicated under the obligation to provide permanent information / Activity of the issuer (acquisition, sale, partnerships, etc.)
Regulatory Filings Classification · 92% confidence The document is a press release announcing 'promising preliminary results' from a clinical study (EXPL-HPV-002) regarding cervical cancer detection using HPV testing. It details interim findings, quotes investigators and the CEO, and discusses future expectations. This type of announcement, focusing on operational or clinical progress rather than mandated periodic financial reporting (like 10-K or IR) or specific corporate actions (like DIV or CAP), typically falls under general Investor Relations communication. Since it is not a full transcript (CT), a formal presentation (IP), or a standard earnings release (ER) which usually focuses on P&L/Balance Sheet figures, the most appropriate category is 'Regulatory Filings' (RNS) as a general announcement of material, non-financial operational news, or potentially 'LTR' if the study results were mandated by a regulatory body, but RNS serves as the best general fit for significant operational updates that aren't explicitly covered elsewhere.
2017-05-10 English
Communiqués au titre de l'obligation d'information permanente / Activité de l'émetteur (acquisitions, cessions, partenariats, …)
Earnings Release Classification · 95% confidence The document is a press release from Genomic Vision announcing 'premiers résultats prometteurs' (promising initial results) from a clinical trial regarding cervical cancer screening. It details study objectives, intermediate findings, and quotes from the principal investigator and the company's CEO. This format—a formal announcement of recent operational or scientific progress, often including financial context or outlook—is characteristic of an Earnings Release (ER) or a general press release related to business updates. Since it focuses on clinical trial results rather than comprehensive financial statements (like 10-K or IR) or a formal earnings call transcript (CT), it best fits the 'Earnings Release' category, which often covers key operational highlights preceding a full report, or a general announcement of significant business progress. Given the focus on results and future expectations, ER is the most appropriate fit among the options, although it is not strictly an 'earnings' release in the traditional sense, it serves the function of releasing key performance/progress indicators to the market. FY 2017
2017-05-10 French

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.